Special issue on melanoma

Cancer Journal

Volumn 18, Issue 2, 2012, Pages 115-116

  Davies, Michael A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; VEMURAFENIB;

BASAL CELL CARCINOMA; CANCER DIAGNOSIS; CANCER INCIDENCE; EDITORIAL; HEALTH CARE COST; HUMAN; MELANOMA; OVERALL SURVIVAL; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; SKIN CANCER; SQUAMOUS CELL CARCINOMA; UNITED STATES;

ANIMALS; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 84859447746     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318250f98d     Document Type: Editorial

References (10)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011. CA Cancer J Clin. 2011;61:212-236.
2. Stern RS. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. Arch Dermatol. 2010;146:279-282.
3. Donaldson M, Coldiron B. No end in sight: the skin cancer epidemic continues. Semin Cutan Med Surg. 2011;30:3-5.
4. Ekwueme DU, Guy GP, Li C, et al. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicityVUnited States, 2000 to 2006. J Am Acad Dermatol. 2011;65:S133-S143.
5. Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol. 2011;65:S17-S25.e3.
6. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipil-imumab in patients with metastatic melanoma. N Engl J Med. 2010;363: 711-723.
7. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364: 2517-2526.
8. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
9. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
10. Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on cancer melanoma staging system. J Clin Oncol. 2001;19: 3622-3634. (Pubitemid 32786275)